



Synthesis of substituted estradiols by the selective aromatization of A-ring of steroidal 19-nor- Δ -4-3-ketones with phenylselenyl halides/hydrogen peroxide

Bindu Santhamma*, Klaus Nickisch

Evestra Inc., San Antonio, TX, USA

ARTICLE INFO

Article history:

Received 16 October 2012

Received in revised form 14 March 2013

Accepted 23 March 2013

Available online 9 April 2013

Keywords:

Substituted estradiols

Aromatization

Phenylselenyl halides

ABSTRACT

A range of 6-, 7-, and 11-substituted estradiols were synthesized by the selective aromatization of the A-ring of 19-nor steroids using phenylselenyl halides followed by oxidation with hydrogen peroxide. Established methods utilizing copper(II) halides failed or have given poor yields with these substrates.

© 2013 Elsevier Ltd. All rights reserved.

1. Introduction

Estrogens are a class of physiologically active steroid molecules that play a crucial role in reproduction as well as in the maintenance of normal human physiology. Their widespread uses as pharmaceutical agents in hormonal birth control, hormone replacement therapy and for other gynecological indications make their synthesis attractive to date [1–4]. One of the key steps in the total synthesis of estrogens is the aromatization of the A-ring. A variety of methods are reported in the literature for the A-ring aromatization of 19-nor steroids, which spans from microbiological [5] to chemical methods, namely selenium dioxide and copper bromide [6,7]. As a part of an ongoing project for the development of new estrogens, we had to accomplish the selective aromatization of a number of highly substituted 19-nor steroids. Most of the conventional methods, however, failed or gave very poor yields when applied to our substrates. Herein we describe our efforts in the selective A-ring aromatization of 6-, 7-, and 11-substituted 19-nor steroids using a combination of phenylselenyl halides and hydrogen peroxide. Although the use of this methodology has been reported in the literature for the transformation of 19-nor testosterone to estrone [8], it gained very limited attention in steroid chemistry. We have investigated the scope and use of this reagent combination in the selective aromatization of a number of highly substituted 19-nor steroids where the standard methods failed and our results are summarized below.

2. Experimental

General: NMR spectra were recorded at 300 (^1H) and 75 (^{13}C) MHz, respectively, on a Bruker ARX-300 MHz NMR spectrometer. Chemical shifts (δ) are reported relative to TMS (^1H) and CDCl_3 (^{13}C) as the internal standards. Coupling constants (J) are reported in Hertz (Hz). High-resolution mass spectral analysis was conducted on an Agilent 6224 ESI-TOF mass spectrometer with sample introduction by infusion. Melting points were recorded on a MEL-TEMP[®] 3.0 melting point apparatus and are uncorrected. Infrared spectra were recorded on a Thermo-Nicolet AVATAR 370 FT-IR machine. 'Flash column' chromatography was performed on 32–64- μm silica gel obtained from EM Science (Gibbstown, NJ). Thin-layer chromatography (TLC) analyses were carried out on silica gel GF (Analtech) glass plates (2.5 cm \times 10 cm with 250 μm layer and pre-scored). Most chemicals and solvents were analytical grade and used without further purification. Commercial reagents were purchased from Aldrich Chemical Company (Milwaukee, WI). All experiments were carried out under inert atmosphere using dry nitrogen. For reactions that gave known compounds, the products were compared with reported spectroscopic data.

2.1. Synthesis of starting materials

All starting materials were prepared according to reported literature procedures. Compound **1** was synthesized from the known 3-methoxy-11 β , 17 β -dihydroxy estra-1,3,5(10)-tirene by a Birch reduction [9], benzylation of 11 and 17 hydroxyl groups followed by acid hydrolysis [10]. Compounds **3a**, **3b**, **3c**, **3d** [11], **5** [12] and **7** [13] were synthesized following reported procedures. Compound

* Corresponding author. Tel.: +1 2106733300x116.

E-mail address: bsanthamma@evestra.com (B. Santhamma).

4a is a known compound and spectral data were found to be matching [14].

2.2. General procedure for the aromatization reaction

2.2.1. 11 β ,17 β -Dibenzoyloxy *estra-1,3,5(10)*-triene-3-ol (**2**)

A solution of compound **1** (1 g, 2.12 mmol) in anhydrous THF (10 mL) was cooled to -78°C and was treated dropwise with a 1 M THF solution of lithium bis(trimethylsilyl)amide (LiHMDS) (4.24 mL, 4.24 mmol). The resulting solution was stirred at -78°C for 1.5 h. A solution of phenylselenenyl chloride in anhydrous THF (10 mL) was added to the reaction mixture at -78°C and was stirred for 3 h with warming to 0°C . TLC showed complete conversion of starting material to the product. The reaction was quenched by the addition of saturated ammonium chloride (20 mL) and was extracted with EtOAc. The combined organic layers were washed with water, brine and were dried over anhydrous sodium sulfate. The solvent was removed *in vacuo* to afford crude **1a** as a dark brown viscous liquid (1.25 g). The crude **1a** thus obtained was dissolved in THF (20 mL) and was treated with 30% hydrogen peroxide solution (0.5 mL, 4.24 mmol). The reaction mixture was stirred at room temperature for 3 h and was quenched by the addition of saturated $\text{Na}_2\text{S}_2\text{O}_3$ solution. The reaction mixture was extracted with EtOAc (2×30 mL) and the combined organic layers were washed with water, brine and dried over anhydrous sodium sulfate. The solvent was removed *in vacuo* to give crude **2** (1 g) as a dark brown solid, which was purified by chromatography on a silica column eluting with 20% EtOAc–hexane solvent system. This gave the pure compound **2** as a pale yellow solid (530 mg, 53%) m.p. $152\text{--}153^{\circ}\text{C}$ IR (cm^{-1}) 3303, 2871, 1582, 1099, 1041, 701.

^1H NMR (δ , 300 MHz, CDCl_3) 1.10 (s, 3H, $-\text{CH}_3$), 3.48 (t, $J = 8.4$ Hz, $-\text{CHO}$), 4.28 (m, 1H, CHO), 4.36 (d, $J = 11.7$ Hz, 1H, $-\text{OCH}_2$), 4.58 (m, 3H, $-\text{OCH}_2$), 4.68 (s, 1H, $-\text{OH}$), 6.53 (m, 2H, ArH), 6.81 (d, $J = 7.9$ Hz, 1H, $-\text{ArH}$), 7.17 (m, 2H, ArH), 7.28 (m, 4H, $-\text{ArH}$), 7.37 (m, 4H, $-\text{ArH}$). ^{13}C NMR (75 MHz, CDCl_3) 13.3, 23.0, 27.2, 27.7, 29.7, 33.6, 38.6, 43.3, 49.5, 51.2, 59.4, 70.4, 71.6, 74.0, 88.7, 112.6, 115.5, 127.4, 127.5, 128.0, 128.3, 129.2, 138.4, 138.9, 139.3, 152.9. HRMS calculated for $\text{C}_{32}\text{H}_{35}\text{O}_3$ (M/Z–H) 467.2586. Found 467.2632.

2.2.2. 11 β -Methyl-*estra-1,3,5(10)*-triene-3, 17 β -diol (**4a**)

Compound **4a** was prepared from **3a** in 60% yield following the general procedure described for **2** except phenylselenenyl bromide was used in place of phenylselenenyl chloride and the following amounts of reagents were used: **3a** (288 mg, 1 mmol), phenylselenenyl bromide (472 mg, 2 mmol), LiHMDS (5 mL, 5 mmol), 30% hydrogen peroxide (0.17 mL, 1.5 mmol). The product was purified using a silica column eluting with 30% EtOAc–hexane solvent system. **4a**: 170 mg, pale yellow amorphous solid. IR (cm^{-1}) 3336, 2908, 1616, 1246, 1058, 822. ^1H NMR (δ , 300 MHz, CDCl_3) 0.88 (m, 6H, $2 \times -\text{CH}_3$), 3.71 (m, 1H, $-\text{CHO}$), 4.68 (s, 1H, $-\text{OH}$), 6.54 (m, 1H, $-\text{ArH}$), 6.63 (dd, $J_1 = 2.7$ Hz, $J_2 = 5.7$ Hz, $-\text{ArH}$), 7.05 (d, $J = 8.3$ Hz, $-\text{ArH}$). ^{13}C NMR (75 MHz, CDCl_3) 14.8, 17.3, 23.2, 26.8, 30.1, 30.4, 30.5, 33.8, 43.4, 44.4, 48.9, 51.6, 83.1, 112.9, 115.2, 128.1, 130.4, 139.1, 152.9.

2.2.3. 17 β -*tert*-butyldimethylsilyloxy, 11 β -methyl-*estra-1,3,5(10)*-triene-3-ol (**4b**)

Compound **4b** was prepared from **3b** in 79% yield following the general procedure described for **2** except phenylselenenyl bromide was used in place of phenylselenenyl chloride and the following amounts of reagents were used: **3b** (403 mg, 1 mmol), phenylselenenyl bromide (283 mg, 1.2 mmol), LiHMDS (3 mL, 3 mmol), 30% hydrogen peroxide (0.13 mL, 1.2 mmol). The product was purified using a silica column eluting with 10% EtOAc–hexane solvent system. **4b**: 320 mg, white amorphous solid. IR (cm^{-1}) 3303, 2883,

1603, 1251, 1087, 827. ^1H NMR (δ , 300 MHz, CDCl_3) 0.02 and 0.04 (2s, 6H, $-\text{Si}(\text{CH}_3)_2$), 0.80 (d, $J = 7$ Hz, 3H, $-\text{CH}_3$), 0.89 (m, 12H, $4 \times -\text{CH}_3$), 3.60 (t, $J = 8.5$ Hz, 1H, $-\text{CHO}$), 6.57 (m, 1H, $-\text{ArH}$), 6.66 (dd, $J_1 = 3$ Hz, $J_2 = 6$ Hz, 1H, $-\text{ArH}$), 7.01 (d, $J = 8.4$ Hz, 1H). ^{13}C NMR (75 MHz, CDCl_3) -4.8 , -4.5 , 15.1, 17.3, 18.1, 23.4, 25.9, 26.9, 30.2, 30.5, 30.9, 36.7, 43.7, 45.0, 51.3, 83.0, 91.9, 113.2, 115.4, 127.9, 129.7, 138.9, 153.8. HRMS calculated for $\text{C}_{25}\text{H}_{39}\text{O}_2\text{Si}$ (M/Z–H) 399.2718. Found 399.2719.

2.2.4. 17 β -*tert*-Butyldimethylsilyloxy, 7 α ,11 β -dimethyl-*estra-1,3,5(10)*-triene-3-ol (**4c**)


Compound **4c** was prepared from **3c** in 69% yield following the general procedure described for **2** except phenylselenenyl bromide was used in place of phenylselenenyl chloride and the following amounts of reagents were used: **3c** (353 mg, 0.85 mmol), phenylselenenyl bromide (401 mg, 2 mmol), LiHMDS (2.6 mL, 2.6 mmol), 30% hydrogen peroxide (0.13 mL, 1.1 mmol). The product was purified using a silica column eluting with 10% EtOAc–hexane solvent system. **4c**: 180 mg, white crystalline solid. m.p. $179\text{--}181^{\circ}\text{C}$. IR (cm^{-1}) 3307, 2900, 1502, 1246, 1112, 839. ^1H NMR (δ , 300 MHz, CDCl_3) 0.03 (2s, 6H, $-\text{Si}(\text{CH}_3)_2$), 0.80 (d, $J = 7$ Hz, 3H, $-\text{CH}_3$), 0.85 (m, 6H, $2 \times -\text{CH}_3$), 0.9 (s, 9H, $3 \times -\text{CH}_3$), 3.62 (t, $J = 8.1$ Hz, 1H, $-\text{CHO}$), 6.52 (m, 1H, $-\text{ArH}$), 6.62 (dd, $J_1 = 3$ Hz, $J_2 = 6$ Hz, 1H, $-\text{ArH}$), 7.03 (d, $J = 8.1$ Hz, 1H). ^{13}C NMR (75 MHz, CDCl_3) -4.7 , -4.5 , 12.3, 15.0, 17.4, 18.1, 22.7, 25.9, 27.7, 30.8, 30.9, 35.8, 38.2, 42.5, 43.9, 44.9, 45.7, 48.2, 83.0, 113.0, 116.0, 127.9, 130.0, 137.6, 152.9. HRMS calculated for $\text{C}_{26}\text{H}_{41}\text{O}_2\text{Si}$ (M/Z–H) 413.2876. Found 413.2874.

2.2.5. 13 β -Ethyl-11-methylene-18-nor-*estra-1,3,5(10)*-triene-3,17 β -ol (**6a**)


Compound **6a** was prepared from **5a** in 59% yield following the general procedure described for **2** except phenylselenenyl bromide was used in place of phenylselenenyl chloride and the following amounts of reagents were used: **5a** (460 mg, 1.5 mmol), phenylselenenyl bromide (722 mg, 3.1 mmol), LiHMDS (7.7 mL, 7.7 mmol), 30% hydrogen peroxide (0.17 mL, 1.5 mmol). The product was purified using a silica column eluting with 30% EtOAc–hexane solvent system. **6a**: 260 mg, pale yellow amorphous solid. IR (cm^{-1}) 3320, 2938, 1616, 1288, 1058, 801. ^1H NMR (δ , 300 MHz, CDCl_3) 1.07 (t, $J = 7.5$ Hz, 3H, $-\text{CH}_3$), 3.93 (t, $J = 7.9$ Hz, 1H, $-\text{CHO}$), 4.74 (bs, 1H, $-\text{OH}$), 4.87 (s, 1H, $=\text{CH}$), 4.98 (s, 1H, $=\text{CH}$), 6.58 (s, 1H, $-\text{ArH}$), 6.63 (dd, $J_1 = 3$ Hz, $J_2 = 6$ Hz, 1H, $-\text{ArH}$), 7.21 (d, $J = 8.2$ Hz, 1H, $-\text{ArH}$). ^{13}C NMR (75 MHz, CDCl_3) 9.2, 18.8, 22.0, 26.8, 30.7, 31.3, 41.6, 44.3, 47.2, 51.3, 52.2, 83.3, 109.0, 112.4, 115.4, 127.9, 131.4, 139.5, 147.5, 153.2. HRMS calculated for $\text{C}_{20}\text{H}_{25}\text{O}_2$ (M/Z–H) 297.1855. Found 297.1860.

2.2.6. 13 β -Ethyl-11-methylene-18,19-dinor-17 α -pregna-1,3,5(10)-triene-20-yne-3,17 β -ol (**6b**)


Compound **6b** was prepared from **5b** in 84% yield following the general procedure described for **2** except phenylselenenyl bromide was used in place of phenylselenenyl chloride and the following amounts of reagents were used: **5b** (324 mg, 1 mmol), phenylselenenyl bromide (472 mg, 2 mmol), LiHMDS (5 mL, 5 mmol), 30% hydrogen peroxide (0.22 mL, 2 mmol). The product was purified using a silica column eluting with 40% EtOAc–hexane solvent system. **6b**: 270 mg, pale yellow amorphous solid. IR (cm^{-1}) 3301, 2940, 2245, 1611, 1246, 1053, 905. ^1H NMR (δ , 300 MHz, CDCl_3) 1.06 (t, $J = 7.2$ Hz, 3H, $-\text{CH}_3$), 2.05 (s, 1H), 3.03 (d, $J = 10$ Hz, 1H), 4.72 (s, 1H, $-\text{OH}$), 4.88 (s, 1H, $=\text{CH}$), 5.00 (s, 1H, $=\text{CH}$), 6.56 (d, $J = 2.6$ Hz, 1H, $-\text{ArH}$), 6.63 (dd, $J_1 = 2.6$ Hz, $J_2 = 6$ Hz, 1H, $-\text{ArH}$), 7.21 (d, $J = 8.4$ Hz, 1H, $-\text{ArH}$). ^{13}C NMR (75 MHz, CDCl_3) 9.3, 19.9, 21.7, 26.9, 30.7, 40.0, 40.4, 42.0, 50.9, 52.1, 74.2, 81.1, 87.8, 109.2, 112.5, 115.3, 127.8, 131.3, 139.5, 147.8, 153.1.



Scheme 1. Synthesis of compound 2



Scheme 2. Syntheses of compounds 4a, 4b and 4c



Scheme 3. Syntheses of compounds 6a and 6b

2.2.7. 17 β -tert-Butyldimethylsilyloxy, 6,6-cyclopropyl-estra-1,3,5(10)-triene-3-ol (8)

Compound **8** was prepared from **7** in 37% yield following the general procedure described for **2** except phenylselenenyl bromide was used in place of phenylselenenyl chloride and the following amounts of reagents were used: **7** (580 mg, 1 mmol), phenylselenenyl bromide (396 mg, 1.2 mmol), LiHMDS (3 mL, 3 mmol), 30% hydrogen peroxide (0.23 mL, 2.1 mmol). The product was purified using a silica column eluting with 40% EtOAc–hexane solvent system. **8**: 210 mg, pale yellow amorphous solid. IR (cm^{-1}) 3362, 2921, 1620, 1251, 1099, 839. 1H NMR (δ , 300 MHz, $CDCl_3$) 0.04 (s, 3H, $-Si(CH_3)_2$), 0.05 $-Si(CH_3)_2$, 0.77 (s, 4H, $-CH_2$), 0.79 (s, 3H, $-CH_3$), 0.91 (s, $-Si-C-(CH_3)_3$) 3.65 (t, $J = 8.1$ Hz, 1H), 4.8 (bs, 1H, $-OH$), 6.12 (d, $J = 2.5$ Hz, 1H, $-ArH$), 6.58 (dd, $J_1 = 3$ Hz, $J_2 = 5.6$ Hz, 1H, $-ArH$), 7.15 (d, $J = 8.6$ Hz, 1H). ^{13}C NMR (75 MHz, $CDCl_3$) $-4.8, -4.5, 11.3, 16.7, 18.1, 18.5, 23.2, 23.5, 25.3, 25.6, 30.9, 34.7, 37.9, 39.8, 43.5, 44.7, 49.3, 81.7, 108.4, 111.9, 126.2, 133.2, 143.7, 153.8$. HRMS calculated for $C_{26}H_{39}O_2Si$ ($M/Z-H$) 411.2720. Found 411.2715.


3. Results and discussion

Our studies commenced with the aromatization of 11,17-dibenzyloxy 19-nor steroid derivative **1** (Scheme 1).

As shown in the above scheme, substrate **1** was deprotonated at C-2 with LiHMDS at -78 °C and the resulting enolate was trapped with phenylselenenyl chloride. The resulting phenylselenenyl adduct was oxidized using hydrogen peroxide to afford the 11-, 17-dibenzyloxy estradiol derivative **2** in 53% yield. Comparable yield of **2** was obtained when phenylselenenyl bromide and hydrogen peroxide were used as the reagents. This method has been widely used for the conversion of ketones to α,β -unsaturated ketones [15–17]. This selective aromatization of substrate **1** with reagents such as copper(II) bromide and selenium dioxide gave a complex reaction mixture. It is already reported in the literature that selective aromatization of 3-keto- Δ -4, 19-nor steroids are substrate dependent and conventional reagents like copper bromide fails in substrates having bulky substituents at position 11 and other positions [18].

With the encouraging results obtained in the case of substrate **1**, we extended the present study to 11-substituted derivatives and the results are summarized in the following scheme (Scheme 2).

This methodology was successfully applied for the A-ring aromatization of 13-ethyl, 19-nor Δ -4-3-ketones (Scheme 3), a nota-



Scheme 4. Synthesis of compound 8

ble example being etonogestrel (**5b**), a steroidal progestin largely used in hormonal birth control. The A-ring aromatized etonogestrel derivative **6b** was obtained in an excellent yield of 84%. It should be noted that this transformation was previously achieved only through microbial oxidation [19].

This methodology was also tried on 6-substituted 3-keto- Δ -4, 19-nor steroid **7**. All conventional methods of aromatization failed when applied to this substrate. As shown in Scheme 4, the corresponding estradiol derivative was obtained in a moderate yield of 37%.

In conclusion, we studied the scope of using phenylselenenyl halides and hydrogen peroxide for the selective A-ring aromatization of substituted 19-nor steroids. It is also established that, this methodology is substituent independent and gave moderate to excellent yields of a variety of substituted estradiol derivatives.

References

- [1] Rossouw JE, Anderson GL, Prentice RL, Lacroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *J Am Med Assoc* 2002;288: 321–333A.
- [2] Hays J. Effects of estrogen plus progestin on health-related quality of life. *N Engl J Med* 2003;348:1839–54.
- [3] Cleve A, Fritzemeier KH, Haendler B, Heinrich N, Möller C, Schwede W, et al. Pharmacology and clinical use of sex steroid hormone receptor modulators. *Handb Exp Pharmacol* 2012;214:543–87.
- [4] Yang LP, Plosker GL. Norgestrel acetate/estradiol: in oral contraception. *Drugs* 2012;72(14):1917–28.
- [5] Brosa C, Ferrer JC, Malet C, Amezcaga JM. Synthesis of 3-methoxyestra-1,3,5(10),6-tetraen-17-one. *J Org Chem* 1989;54:3984–5.
- [6] Rao PN, Cessac JW, Kim HK. Preparative chemical methods for aromatization of 19-nor- Δ ⁴-3-oxosteroids. *Steroids* 1994;59:621–7.
- [7] Ali H, van Lier JE. Synthesis and receptor binding affinity of 7 α - and 17 α -substituted 2- and 4-chloroestradiol derivatives. *J Chem Soc Perkin Trans 1* 1991:2485–9.
- [8] Al-Hassan MI. Conversion of 19-nortestosterone to β -estradiol. *Synth Commun* 1989;453–61.
- [9] Choe YS, Lidstroem PJ, Chi DY, Bonasera TA, Welch MJ, Katzenellenbogen JA. Synthesis of 11 β -[¹⁸F] fluoro-5 α -dihydrotestosterone and 11 β -[¹⁸F] fluoro-19-

- nor-5 α -dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution. *J Med Chem* 1995;38:816–25.
- [10] Labaree DC, Zhang JX, Harris HA, Reynolds TY, Hochberg RB. Synthesis and evaluation of B-, C- and D-ring substituted estradiol carboxylic acid esters as locally active estrogens. *J Med Chem* 2003;46: 1886–1904.
- [11] Blye RP, Kim HK. Nandrolone 17 β -carbonates. WO 2006/083618 A1.
- [12] Shwarz S, Ring S, Weber G, Teichmuller G, Palme HJ, Pfeiffer C, et al. Synthesis of 13-ethyl-11-methylene-18, 19-dinor-17 α -pregn-4-en-20-yn-17-ol (desogestrel) and its main metabolite 3-oxo desogestrel. *Tetrahedron* 1994;50:10709–20.
- [13] Vlasios G, Belmont M, Holden KG, Strafford NJ. 6,6-Ethylene-19-nortestosterones. US 1968/3,373,157.
- [14] Baran JS, Langford DD, Laos I, Liang CD. The synthesis of 11 β -alkyl-19-norsteroids: a novel class of potent steroid hormones-I: The synthesis of 11 β -methyl and 11 β -ethylestradiol. *Tetrahedron* 1977;33:609–16.
- [15] Clive DJ. Modern selenium chemistry. *Tetrahedron* 1978;34: 1049–32.
- [16] Engman L. Methods for the introduction of a phenylselenium dichloride group into the α -position of carbonyl compounds. Syntheses of enones. *J Org Chem* 1988;53:4031–7.
- [17] Detty MR. Oxidation of selenides and tellurides with positive halogenating species. *J Org Chem* 1980;45:274–9.
- [18] Ahmed N, Van Lier JE. A novel and stereo selective synthesis of 7 α -alkynylestra-1,3,5(10)-triene-3,17 β -estradiol. *Tetrahedron Lett* 2007;48:5723–6.
- [19] Helmut G, Schoen R, Michael R, Helmut K, Katrin U, Gerhard H. Preparation of 3-ketodesogestrel metabolites by microbial transformation and chemical synthesis. *Steroids* 1997;62:437–43.